Search results for "From ACP Journal Club"
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations
Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found.
https://diabetes.acponline.org/archives/2016/08/12/6.htm
12 Aug 2016
One-step screening approach detected more gestational diabetes than two-step approach but did not improve clinical outcomes
A screening approach that finds more cases of gestational diabetes without improving patient outcomes introduces considerable burden and costs to patients, clinicians, and medical systems, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/08/13/6.htm
13 Aug 2021
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/09/10/7.htm
10 Sep 2021
In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years
An industry-funded trial found that those who took empagliflozin had lower rates of mortality, including from cardiovascular (CV) events, than those on placebo. A commentary in ACP Journal Club called the trial results fascinating but said they are not yet sufficient to change practice.
https://diabetes.acponline.org/archives/2016/02/12/5.htm
12 Feb 2016
Incretin use was not associated with increased risk for acute pancreatitis
Patients who took incretin-based drugs had the same risk of acute pancreatitis as those who took other hypoglycemic medications or took neither type of drug, a case-control study found.
https://diabetes.acponline.org/archives/2015/07/10/6.htm
10 Jul 2015
In overweight or obese patients with diabetes, a lifestyle intervention increased weight loss at 8 years
Receiving an intensive lifestyle intervention (ILI) rather than traditional diabetes support and education (DSE) increased weight loss in about 5,000 middle-aged adults with type 2 diabetes.
https://diabetes.acponline.org/archives/2014/07/11/5.htm
11 Jul 2014
In metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels
Patients whose diabetes was inadequately controlled on metformin showed similar weight loss, improvement in HbA1c, and adverse events whether they took dulaglutide or liraglutide, a trial found.
https://diabetes.acponline.org/archives/2014/12/12/6.htm
12 Dec 2014
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
The data suggest that renoprotection from sodium-glucose cotransporter-2 (SGLT-2) inhibitors may not require the presence of diabetes or albuminuria and may be effective even in patients with worse renal function, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/03/13/6.htm
13 Mar 2020
SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
An ACP Journal Club commentary called the results of this real-world, retrospective study reassuring regarding concerns about associations of urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
https://diabetes.acponline.org/archives/2020/01/10/8.htm
10 Jan 2020
Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria
In a trial of more than 1,000 diabetic patients with proteinuria, adding an ACE inhibitor to an ARB didn't improve estimated glomerular filtration rate and increased risk for hyperkalemia and acute kidney injury, so the trial was halted early.
https://diabetes.acponline.org/archives/2014/05/09/6.htm
9 May 2014